EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): StudyFirst CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher) 22.11.2023 / 16:02 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin/Würzburg, 22 November 202.
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word: Study
First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium Anditixafortide .
EQS Voting Rights Announcement: Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler Strahlen- und Medizintechnik AG: Release according to Article 40, Section 1 of.